AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,141,000 | +65.4% | 49,436 | +1.2% | 0.00% | +50.0% |
| Q3 2020 | $690,000 | -2.0% | 48,851 | +4.7% | 0.00% | -33.3% |
| Q2 2020 | $704,000 | +83.3% | 46,664 | +12.4% | 0.00% | +50.0% |
| Q1 2020 | $384,000 | -25.3% | 41,526 | -21.3% | 0.00% | 0.0% |
| Q4 2019 | $514,000 | +144.8% | 52,747 | +101.7% | 0.00% | +100.0% |
| Q3 2019 | $210,000 | -34.8% | 26,151 | +1.5% | 0.00% | 0.0% |
| Q2 2019 | $322,000 | +8.8% | 25,762 | +18.5% | 0.00% | 0.0% |
| Q1 2019 | $296,000 | +52.6% | 21,736 | +7.5% | 0.00% | 0.0% |
| Q4 2018 | $194,000 | -4.0% | 20,211 | +21.2% | 0.00% | 0.0% |
| Q3 2018 | $202,000 | -15.8% | 16,677 | +8.6% | 0.00% | 0.0% |
| Q2 2018 | $240,000 | +1.3% | 15,354 | -2.5% | 0.00% | 0.0% |
| Q1 2018 | $237,000 | +4.9% | 15,750 | +0.5% | 0.00% | 0.0% |
| Q4 2017 | $226,000 | -2.2% | 15,673 | +2.3% | 0.00% | 0.0% |
| Q3 2017 | $231,000 | +63.8% | 15,326 | +9.6% | 0.00% | 0.0% |
| Q2 2017 | $141,000 | +60.2% | 13,986 | +13.5% | 0.00% | 0.0% |
| Q1 2017 | $88,000 | – | 12,323 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |